Narcotic Antagonists

"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents inhibiting the effect of narcotics on the central nervous system.

Descriptor ID	D009292
MeSH Number(s)	D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
Concept/Terms	Narcotic Antagonists Narcotic Antagonists Antagonists, Narcotic Opioid Receptor Antagonists Antagonists, Opioid Receptor Receptor Antagonists, Opioid Opioid Antagonists Antagonists, Opioid Competitive Opioid Antagonists Competitive Opioid Antagonists Antagonists, Competitive Opioid Opioid Antagonists, Competitive

Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Narcotic Antagonists [D27.505.696.543]
Peripheral Nervous System Agents [D27.505.696.663]
Sensory System Agents [D27.505.696.663.850]
Narcotic Antagonists [D27.505.696.663.850.512]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Narcotic Antagonists [D27.505.954.427.550]

Below are MeSH descriptors whose meaning is related to "Narcotic Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.

Bar chart showing 42 publications over 22 distinct years, with a maximum of 4 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	3	3
1997	0	1	1
1998	1	0	1
1999	1	2	3
2000	1	2	3
2002	0	2	2
2003	1	1	2
2004	0	2	2
2005	1	0	1
2006	1	1	2
2007	0	1	1
2008	1	1	2
2011	1	3	4
2012	0	2	2
2013	0	3	3
2014	1	0	1
2016	0	2	2
2019	1	1	2
2020	0	1	1
2021	0	2	2
2023	0	1	1
2024	0	1	1

Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.

Tatara E, Ozik J, Pollack HA, Schneider JA, Friedman SR, Harawa NT, Boodram B, Salisbury-Afshar E, Hotton A, Ouellet L, Mackesy-Amiti ME, Collier N, Macal CM. Agent-Based Model of Combined Community- and Jail-Based Take-Home Naloxone Distribution. JAMA Netw Open. 2024 Dec 02; 7(12):e2448732.

View in: PubMed
Abbasloo E, Esmaeili-Mahani S, Kobeissy F, Currier Thomas T. Evidence for the Induction of Analgesic Cross-Tolerance Between Opioid and Apelin/APJ Systems in Male Rats. J Stud Alcohol Drugs. 2024 Sep; 85(5):704-712.

View in: PubMed
Luo SX, Feaster DJ, Liu Y, Balise RR, Hu MC, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry. 2024 01 01; 81(1):45-56.

View in: PubMed
Brandt L, Hu MC, Liu Y, Castillo F, Odom GJ, Balise RR, Feaster DJ, Nunes EV, Luo SX. Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. Am J Psychiatry. 2023 05 01; 180(5):386-394.

View in: PubMed
Santiago D, Rosario Y, Melin K, Duconge J, Roman L, Gonzalez A, Venkataramanan R. Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study. P R Health Sci J. 2021 12; 40(4):192-194.

View in: PubMed
Saraiya P, Hutchins SS, Crump S, Morgan J, Wilkinson T, Walker CD, Taylor B. Availability of Naloxone in 2 Underserved Urban Communities in Georgia. J Public Health Manag Pract. 2021 May-Jun 01; 27(Suppl 3):S179-S185.

View in: PubMed
Melin K, Santiago Qui?ones D, Rodr?guez-D?az CE. Socially distant and out of reach: Unintended consequences of COVID-19 prevention efforts on transgender and gender non-binary populations in Puerto Rico. J Subst Abuse Treat. 2021 03; 122:108209.

View in: PubMed
Ettienne EB, Ofoegbu A, Maneno MK, Briggs J, Ezeude G, Williams S, Walker C, Chapman E. Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort. J Natl Med Assoc. 2019 Dec; 111(6):674-681.

View in: PubMed
Derefinko KJ, Salgado Garc?a FI, Talley KM, Bursac Z, Johnson KC, Murphy JG, McDevitt-Murphy ME, Andrasik F, Sumrok DD. Adverse childhood experiences predict opioid relapse during treatment among rural adults. Addict Behav. 2019 09; 96:171-174.

View in: PubMed
Lutfy K, Parikh D, Lee DL, Liu Y, Ferrini MG, Hamid A, Friedman TC. Prohormone convertase 2 (PC2) null mice have increased mu opioid receptor levels accompanied by altered morphine-induced antinociception, tolerance and dependence. Neuroscience. 2016 08 04; 329:318-25.

View in: PubMed

People

Explore

Similar Concepts

Top Journals